Search clinical trials for: Daratumumab

Total 315 results

Celgene

Active, not recruiting

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom
Mayo Clinic

Recruiting

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Plasma Cell Myeloma

United States
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
Pfizer

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)

Multiple Myeloma

Japan, Taiwan, Canada, Spain, Australia, Italy, Czechia, Korea, Republic of, France, Greece, Israel, Poland, Germany
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (MonumenTAL-3)

Relapsed or Refractory Multiple Myeloma

United States, Korea, Republic of, Italy, Taiwan, China, Germany, Israel, Turkey, Japan, France, United Kingdom, Brazil, Spain, Czechia, Poland, Belgium, Greece, Netherlands
AbbVie

Recruiting

A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

Relapsed/Refractory Multiple Myeloma

United States, Australia, Israel, United Kingdom
Janssen Research & Development, LLC

Completed

Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
AbbVie

Terminated

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Germany, Israel, Japan, Spain
Nantes University Hospital

Active, not recruiting

An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients (IFM 2018-04)

Multiple Myeloma

France
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Japan, Canada, Netherlands, Denmark, Sweden, Korea, Republic of, Russian Federation, Greece
European Myeloma Network
Janssen Research & Development, LLC

Active, not recruiting

Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone (EMN14)

Multiple Myeloma

Netherlands, Belgium, Germany, Spain, Czechia, Greece, Italy, Denmark, Serbia, Turkey
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
University of Rochester

Recruiting

Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Multiple Myeloma

United States
Fondazione EMN Italy Onlus

Active, not recruiting

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients (DPd)

Multiple Myeloma | Deletion 17P Syndrome

Italy
Alliance Foundation Trials, LLC.
Celgene; Janssen, LP

Withdrawn

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Relapsed or Refractory Multiple Myeloma
Hellenic Society of Hematology
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Gammopathy, Monoclonal | Haematologic Disease

Greece
Fate Therapeutics

Recruiting

FT576 in Subjects With Multiple Myeloma

Multiple Myeloma | Myeloma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

Multiple Myeloma

Canada, United States, Belgium, Korea, Republic of, United Kingdom, Sweden, Italy, Denmark, Japan, Taiwan, China, Germany, Spain, France, Netherlands, Turkey, Russian Federation, Poland, Greece, Argentina, Brazil
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
Takeda

Completed

A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma

United States, Netherlands, Czechia, France, Greece, Poland
Hospital Federal de Bonsucesso

Completed

Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy

Postoperative Nausea and Vomiting

Brazil
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Hellenic Society of Hematology
GlaxoSmithKline

Not yet recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Neoplasms | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Corneal Disease | Multiple Myeloma in Relapse | Gammopathy, Monoclonal | Haematologic Disease
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab

Multiple Myeloma

Korea, Republic of, Russian Federation, Spain, Germany, Belgium, Denmark, Greece, France, United States, Ukraine, Poland
University of Colorado, Denver
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse

United States
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Active, not recruiting

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Multiple Myeloma

United States
Celgene

Active, not recruiting

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Multiple Myeloma

United States, Canada, Japan, Puerto Rico
Celgene

Terminated

A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003)

Multiple Myeloma

United States, Canada, Spain, Italy, Denmark, United Kingdom, Belgium, Sweden, Germany
Attaya Suvannasankha
Janssen Scientific Affairs, LLC; Indiana Institute for Medical Research

Withdrawn

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

Multiple Myeloma

United States
Tel-Aviv Sourasky Medical Center

Completed

Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients (KyDaR)

Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Myeloma, Plasma-Cell

Israel
Vejle Hospital

Completed

"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab " (DARA)

Multiple Myeloma

Denmark
Nantes University Hospital
Janssen Pharmaceutica

Not yet recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma (IFm2022-01)

Multiple Myeloma

France
Memorial Sloan Kettering Cancer Center
Janssen Pharmaceuticals

Recruiting

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple Myeloma | Monoclonal Gammopathy of Renal Significance

United States
US Oncology Research
Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Plasma Cell Myeloma | Myeloma-Multiple | Myeloma Multiple | Kahler Disease | Myeloma, Plasma Cell | Myelomatosis

United States
Andrew Yee, MD
Janssen Research & Development, LLC; Amgen

Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Multiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in Relapse

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)

Multiple Myeloma

United States, Netherlands, Belgium, Korea, Republic of, United Kingdom, Sweden, Denmark, Italy, Japan, Germany, France, Spain, Australia, Israel, Poland, Greece
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)

Multiple Myeloma

United States, Belgium, Germany, Netherlands, Israel, Spain, Saudi Arabia, France
Human Genome Sciences Inc.

Completed

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Germany, Hungary, Romania
Genentech, Inc.
Hoffmann-La Roche

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (CAMMA 1)

Multiple Myeloma

Korea, Republic of, United States, Denmark, Italy, Spain, France, Japan, Israel, United Kingdom, Poland, Australia, Canada, Czechia
Janssen Research & Development, LLC

Completed

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

Multiple Myeloma

Korea, Republic of, Malaysia, China, Taiwan, Hong Kong
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Anaveon AG

Terminated

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Hematologic Diseases | Multiple Myeloma | Refractory Multiple Myeloma | Adult Disease | Relapsed Cancer

Spain, Germany, France, Denmark, Switzerland
University of Heidelberg Medical Center
Janssen Research & Development, LLC; Deutsche Studiengruppe Multiples Myelom...

Recruiting

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX)

Multiple Myeloma

Germany
Janssen Research & Development, LLC

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

Multiple Myeloma

Belgium, Korea, Republic of, Australia, United Kingdom, France, Sweden, Spain, Turkey, Italy, Czechia, Netherlands, Poland, Switzerland, Germany
University of Chicago
Janssen Scientific Affairs, LLC; Amgen

Recruiting

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Multiple Myeloma | Myeloma

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Multiple Myeloma

Canada, United States, Israel, Czechia, Turkey, Germany, United Kingdom, Japan, Netherlands, France, Brazil, Poland, Spain
National University of Ireland, Galway, Ireland
Janssen Pharmaceuticals; Cancer Trials Ireland

Unknown

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) (CyBorD-Dara)

Multiple Myeloma

Ireland
Rajshekhar Chakraborty, MD
Genentech, Inc.

Recruiting

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis

United States
Gilead Sciences

Active, not recruiting

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Czechia, Canada

3

Subscribe